PepGen Inc. (PEPG) stock surged +3.39%, trading at $4.88 on NASDAQ, up from the previous close of $4.72. The stock opened at $4.77, fluctuating between $4.77 and $5.08 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 25, 2026 | 4.77 | 5.10 | 4.77 | 4.88 | 669.02K |
| Mar 24, 2026 | 4.72 | 4.90 | 4.52 | 4.72 | 351.7K |
| Mar 23, 2026 | 4.77 | 4.91 | 4.66 | 4.78 | 657.72K |
| Mar 20, 2026 | 4.77 | 4.84 | 4.50 | 4.70 | 653.78K |
| Mar 19, 2026 | 5.03 | 5.08 | 4.72 | 4.77 | 463.78K |
| Mar 18, 2026 | 5.06 | 5.25 | 4.90 | 5.12 | 302.75K |
| Mar 17, 2026 | 5.32 | 5.32 | 4.89 | 5.09 | 1.51M |
| Mar 16, 2026 | 5.32 | 5.50 | 5.29 | 5.35 | 742.03K |
| Mar 13, 2026 | 6.22 | 6.31 | 5.32 | 5.33 | 1.34M |
| Mar 12, 2026 | 6.25 | 6.29 | 5.99 | 6.15 | 494.67K |
| Mar 11, 2026 | 6.14 | 6.38 | 5.87 | 6.29 | 687.37K |
| Mar 10, 2026 | 5.58 | 6.70 | 5.58 | 6.16 | 734.94K |
| Mar 09, 2026 | 5.62 | 5.98 | 5.49 | 5.57 | 490.13K |
| Mar 06, 2026 | 5.45 | 5.90 | 5.26 | 5.69 | 582.97K |
| Mar 03, 2026 | 6.32 | 6.63 | 6.10 | 6.42 | 517.29K |
| Mar 02, 2026 | 5.97 | 6.69 | 5.87 | 6.53 | 442.43K |
| Feb 27, 2026 | 6.18 | 6.33 | 5.96 | 6.22 | 194.36K |
| Feb 26, 2026 | 6.44 | 6.54 | 6.15 | 6.24 | 240.27K |
| Feb 25, 2026 | 6.59 | 7.05 | 6.33 | 6.40 | 518.12K |
| Feb 24, 2026 | 6.34 | 6.43 | 6.12 | 6.32 | 218.55K |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
| Employees | 79 |
| Beta | 1.87 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep